Menu Search
Equities

Deciphera Pharmaceuticals Inc

D05:MUN

Deciphera Pharmaceuticals Inc

Actions
  • Price (EUR)23.40
  • Today's Change9.80 / 72.06%
  • Shares traded140.00
  • 1 Year change+78.22%
  • Beta--
Data delayed at least 15 minutes, as of Apr 30 2024 15:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.

  • Revenue in USD (TTM)163.36m
  • Net income in USD-194.94m
  • Incorporated2017
  • Employees355.00
  • Location
    Deciphera Pharmaceuticals Inc200 Smith StWALTHAM 02451-0099United StatesUSA
  • Phone+1 (781) 209-6400
  • Fax+1 (302) 655-5049
  • Websitehttps://www.deciphera.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.